查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715449

代謝紊亂藥物市場按治療類別、疾病類型、治療領域、給藥途徑、患者族群、最終用戶和分銷管道分類－2025-2030 年全球預測

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

代謝紊亂治療藥物市場預計在 2023 年達到 698.4 億美元，到 2024 年將以 8.35% 的複合年成長率成長至 755.5 億美元，到 2030 年將達到 1224.9 億美元。

主要市場統計數據
基準年2023年 698.4億美元
預計2024年 755.5億美元
預測年份 2030 1224.9億美元
複合年成長率（%） 8.35%

在當前的醫療保健創新領域，代謝紊亂治療已成為研究人員、臨床醫生和政策制定者關注的重點領域。尖端科學研究與臨床應用的空前結合重新點燃了人們對代謝和內分泌疾病有效治療方法的興趣。隨著科學突破在基因編輯、酵素控制和個人化醫療領域不斷取得新進展，監管機構和醫療保健提供者之間的對話也日益成熟。本執行摘要深入探討了重塑治療格局的變革趨勢、患者需求與疾病複雜性之間的界限以及行業領先企業之間的競爭動態。全面了解這些因素對於相關人員應對複雜情況、最佳化資源配置和利用這個充滿活力的市場中的新機會至關重要。

本報告提供了市場趨勢的整體情況，並指出了行業領導者和市場參與企業面臨的策略挑戰。利用最新的進展和市場數據，該分析強調了代謝紊亂治療如何從傳統方法演變為以患者為中心的現代解決方案。該分析旨在探索嚴謹的科學研究與穩健的市場策略之間的相互作用，為決策者提供推動這一快速發展產業永續成長的藍圖。

改變治療格局的變革

近年來，由於生物醫學研究的創新和監管環境的變化，代謝疾病治療領域發生了重大變化。個人化醫療的出現和數位技術的融合正在加速從傳統治療模式轉向更有針對性的治療方法的演變。在分子生物學和真實世界證據的發展推動下，市場正在經歷重大變化，這些變化正在影響治療方案和臨床最佳實踐。基因治療、酵素替代療法和小分子療法的科學進步共同幫助簡化了患者照護並改善了臨床結果。

基因序列測定和生物資訊技術的突破使研究人員能夠詳細闡明疾病機制，從而發現新的生物標記和治療標靶。這些技術創新大大縮短了從研究到商業化的週期。隨著治療方案不斷改進以解決複雜的代謝紊亂，數據分析和病患監測的融合正在穩步重新定義治療模式。多學科見解的整合創造了設計既有效又具有成本效益的強力治療方法的機會，與全球醫療保健系統的策略重點保持一致。

此外，不斷發展的監管政策正在創造一個鼓勵快速創新的環境。學術機構、研究組織和臨床醫生之間加強合作，為加速核准週期和讓患者更廣泛地獲得最先進治療鋪平了道路。從孤立的研究舉措轉向更全面的跨職能策略，不僅會增加治療方法創新，還能確保其以能夠滿足市場需求的彈性基礎設施為基礎。

市場區隔分析的關鍵見解

深入的細分分析揭示了關鍵見解，為市場動態提供了細緻的理解。該研究檢驗了不同類型的治療策略，包括酵素替代療法、基因療法、藥物療法和小分子療法。治療方法的多樣性反映了代謝疾病領域近期創新的廣度和深度。據觀察，治療分類的重點反映了一種不斷發展的治療機制，旨在改善患者的治療效果並根據個人需求量身定做醫療干預措施。

同時，透過觀察疾病類型可以揭示市場分析的綜合性。將糖尿病分為妊娠糖尿病、1 型糖尿病和第 2 型糖尿病等治療方法凸顯了專門護理途徑的必要性。此外，它還包括高雪氏症、血鐵沉著症、高膽固醇症、粒線體疾病、苯酮尿症 (PKU)、龐貝病以及細分為甲狀腺功能亢進和甲狀腺機能低下症的甲狀腺疾病等。我們也正在嚴格研究其他重要疾病，例如尿素循環障礙和威爾森氏症，以確定每種疾病相關的獨特挑戰和治療機會。

細分進一步擴展到治療領域，詳細說明主要影響內分泌系統、遺傳框架和營養平衡的疾病。本節得出的見解表明，治療方法的多樣性與針對代謝紊亂的嚴重程度和進展而客製化的多樣化治療方法組合直接相關。此外，根據給藥途徑（靜脈注射、口服、皮下）進行細分可以幫助了解患者的便利性和藥物的有效性。該分析還透過考慮成年人、老年人和兒童人群之間的差異來反映患者的人口統計。此外，專注於最終用戶（無論是診所、居家醫療機構、醫院還是專科中心）可以進一步完善您的產品分銷和可訪問性策略。

綜合評估還包括對分銷管道的評估，包括醫院藥局、網路藥局和零售藥局。對這些主題進行綜合分析，可以提供豐富的見解，闡明影響市場成長的潛在趨勢。詳細的細分方法不僅突出了治療發現的方面，而且還規劃了研發的策略性投資藍圖，以確保治療創新與以患者為中心的結果緊密結合。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 生活方式和飲食習慣的改變導致代謝紊亂的發病率增加
      • 增加政府對代謝疾病監測的承諾與支持
    • 限制因素
      • 對產品召回和不利事件的擔憂
    • 機會
      • CRISPR-Cas9 和其他基因組編輯工具在治療代謝疾病方面的技術進步
      • 製藥公司和醫療保健提供者之間合作和投資的增加正在提升潛力
    • 任務
      • 與專利到期以及取得和維護智慧財產權的複雜性相關的問題
  • 市場區隔分析
    • 治療類別：基因治療對代謝失調的益處日益增加
    • 疾病類型：口服藥物在糖尿病治療中的重要性日益增加
    • 治療領域：代謝紊亂藥物在治療內分泌紊亂的成長潛力
    • 給藥途徑：對於口服吸收較差的藥物，靜脈注射有顯著優勢
    • 患者人口統計：增加成年患者代謝藥物的使用，透過改變生活方式來防止病情進展
    • 最終用戶：將代謝紊亂藥物的使用範圍從小型私人診所擴大到大型多專科中心
    • 分銷管道：網路藥局因其便利性和選擇性而變得越來越受歡迎。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 代謝紊亂藥物市場（依治療類別）

  • 酵素替代療法
  • 基因治療
  • 製藥
  • 小分子療法

第7章 代謝失調藥物市場（依疾病類型）

  • 糖尿病
    • 妊娠糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 高雪氏症
  • 血鐵沉著症
  • 高膽固醇症
  • 粒線體疾病
  • 苯酮尿症（PKU）
  • 龐貝氏症
  • 甲狀腺疾病
    • 甲狀腺功能亢進
    • 甲狀腺機能低下症
  • 尿素循環障礙
  • 威爾遜氏症

第8章 代謝紊亂藥物市場（依治療領域）

  • 內分泌失調
  • 遺傳性疾病
  • 營養障礙

第9章 代謝紊亂藥物市場（依給藥途徑）

  • 靜脈
  • 口服
  • 皮下

10. 代謝紊亂藥物市場（依患者人口統計）

  • 成年患者
  • 老年患者
  • 兒科患者

第 11 章 代謝紊亂藥物市場（依最終使用者）

  • 診所
  • 居家照護環境
  • 醫院
  • 專業中心

第 12 章代謝紊亂藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

13.美國代謝紊亂市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太代謝失調藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲代謝紊亂藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica SpA
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
Product Code: MRR-0363DFE03688

The Metabolic Disorders Therapeutics Market was valued at USD 69.84 billion in 2023 and is projected to grow to USD 75.55 billion in 2024, with a CAGR of 8.35%, reaching USD 122.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 69.84 billion
Estimated Year [2024] USD 75.55 billion
Forecast Year [2030] USD 122.49 billion
CAGR (%) 8.35%

In the current landscape of healthcare innovation, metabolic disorders therapeutics have emerged as a critical focus area for researchers, clinicians, and policymakers. The unprecedented convergence of advanced scientific research and clinical applications has driven a renewed interest in effective treatment modalities for metabolic and endocrine disorders. As scientific breakthroughs continue to chart new territories in genetic editing, enzyme regulation, and personalized medicine, the dialogue between regulatory bodies and healthcare providers has matured. This executive summary delves into the transformative trends that are reshaping the therapeutic landscape, the nuanced segmentation of patient needs and disease intricacies, and the competitive dynamics among leading industry players. A comprehensive understanding of these elements is essential for stakeholders looking to navigate complexities, optimize resource allocation, and leverage emerging opportunities within this dynamic market.

The narrative that follows provides a holistic view of market trends and defines the strategic imperatives for both established industry giants and emerging participants. Drawing upon recent advancements and market data, this analysis articulates the evolution of metabolic disorders therapeutics from traditional approaches to modern, patient-centric solutions. It is an invitation to explore the interplay of rigorous scientific inquiry with robust market strategies and offers decision-makers a roadmap to drive sustainable growth in a rapidly advancing sector.

Transformative Shifts Shaping the Therapeutic Landscape

Recent years have witnessed transformative shifts in the metabolic disorders therapeutics landscape, largely propelled by innovations in biomedical research and shifts in regulatory frameworks. The advent of personalized medicine and the integration of digital technologies have accelerated the evolution from conventional treatment paradigms to more targeted therapeutic approaches. The market has experienced significant change driven by developments in both molecular biology and real-world evidence, which in turn have influenced treatment protocols and clinical best practices. Scientific advances in gene therapies, enzyme replacement therapies, and small molecule interventions have collectively contributed to streamlined patient care and improved clinical outcomes.

Technological breakthroughs in genetic sequencing and bioinformatics have enabled researchers to dissect disease mechanisms at a granular level, leading to the discovery of novel biomarkers and therapeutic targets. These innovations have dramatically shortened the cycle from research to product commercialization. As treatment protocols are honed to address complex metabolic disorders, the convergence of data analytics and patient monitoring is steadily redefining therapeutic landscapes. The integration of multidisciplinary insights has created opportunities for designing robust treatment regimens that are both efficacious and cost-effective, aligning with the strategic priorities of healthcare systems globally.

Furthermore, evolving regulatory policies have fostered an environment where rapid innovation is encouraged. Enhanced collaboration between academic institutions, research organizations, and clinical practitioners paves the way for faster approval cycles and broader patient access to cutting-edge therapeutics. This shift from siloed research initiatives to more integrated, cross-functional strategies ensures that treatment modalities are not only innovative but are also supported by a resilient infrastructure capable of scaling with market demands.

Key Insights from Market Segmentation Analysis

A deep-dive segmentation analysis uncovers important insights that provide a nuanced understanding of market dynamics. The study examines treatment strategies through the lens of various classifications, such as enzyme replacement therapies, gene therapies, medications and drugs, and small molecule therapy. This diverse range of treatment modalities illustrates the breadth and depth of recent innovations in addressing metabolic disorders. It is observed that the focus on treatment classifications speaks volumes about the evolving therapeutic mechanisms aimed at enhancing patient outcomes and tailoring healthcare interventions to individualized needs.

Simultaneously, an examination by disease type reveals the comprehensive nature of market analysis. Conditions like Diabetes Mellitus, with its subdivisions into gestational diabetes, Type 1 diabetes, and Type 2 diabetes, underscore the need for specialized treatment pathways. Additionally, the study encompasses a spectrum of disorders including Gaucher's Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, and a range of thyroid disorders that are further segmented into hyperthyroidism and hypothyroidism. Other notable conditions such as urea cycle disorders and Wilson's Disease are also rigorously explored to identify the unique challenges and therapeutic opportunities associated with each condition.

The segmentation further extends to therapeutic areas, underlining diseases predominantly affecting endocrine systems, genetic frameworks, and nutritional balance. Insights drawn from this section indicate that the variety of therapeutic avenues is directly linked to a diversified portfolio of treatment modalities that can be tailored to the severity and progression of metabolic disorders. An additional layer of segmentation based on the route of administration-be it intravenous, oral, or subcutaneous-provides an understanding of patient convenience and drug efficacy. The analysis also reflects upon patient demographics by considering differences among adult, geriatric, and pediatric populations. In addition, a focus on the end user, which spans clinics, home care settings, hospitals, and specialty centers, further refines strategies for product distribution and accessibility.

A comprehensive evaluation includes the assessment of distribution channels as well, encompassing hospital pharmacies, online pharmacies, and retail pharmacies. Each of these dimensions offers rich insights that, when collectively analyzed, reveal underlying trends influencing market growth. The detailed segmentation approach not only accentuates the granular aspects of treatment discovery but also charts out a roadmap for strategic investments in research and development, ensuring that therapeutic innovations align closely with patient-centric outcomes.

Based on Treatment Classifications, market is studied across Enzyme Replacement Therapies, Gene Therapies, Medications & Drugs, and Small Molecule Therapy.

Based on Disease Type, market is studied across Diabetes Mellitus, Gaucher's Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, Thyroid Disorders, Urea Cycle Disorders, and Wilson's Disease. The Diabetes Mellitus is further studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes. The Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism.

Based on Therapeutic Areas, market is studied across Endocrine Disorders, Genetic Disorders, and Nutritional Disorders.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Specialty Centers.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Dynamics and Global Market Insights

A regional analysis in the metabolic disorders therapeutics market reveals significant variances in demand, market maturity, and the pace of innovation. In regions such as the Americas, advanced healthcare infrastructure and high patient awareness have fueled strong adoption rates of new therapeutics. This region is characterized by a robust blend of clinical research, increased investment in pharmaceutical development, and proactive regulatory environments that collectively expedite the path from laboratory to market.

Conversely, the landscape in Europe, the Middle East, and Africa is marked by a balance between innovative therapies and traditional treatment modalities. In these areas, a multi-faceted strategy is observed where healthcare systems are progressively integrating modern treatment options with established protocols. The interaction between regulatory changes and evolving patient demographics offers a unique perspective that emphasizes the need for customization in therapeutic development. Incentives provided by both government and regional entities have supported the growth trajectory, while challenges include aligning new treatments with regional health priorities.

The Asia-Pacific region, on the other hand, is witnessing rapid modernization in healthcare facilities coupled with a surge in patient demand for advanced therapeutics. This region demonstrates a dynamic interplay between high population density and escalating incidences of metabolic disorders, driving significant market potential. Increasing investment in infrastructure and technology in these markets is a testament to the rising importance of metabolic disorders therapeutics globally. As regional collaborations expand and international partnerships flourish, the pace of market penetration is expected to accelerate, further bridging the gap between high-demand areas and advanced treatment capabilities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Key Industry Players

The competitive landscape in metabolic disorders therapeutics is both vibrant and highly concentrated, with numerous established players exerting significant influence over market dynamics. Industry leaders, including Abbott Laboratories, AbbVie Inc., and Acadia Pharmaceuticals Inc., have leveraged their extensive research portfolios to drive innovation in treatment development. Amgen Inc. and Amicus Therapeutics, Inc. are renowned for their pioneering works in biologic therapies, while Astellas Pharma Inc. and AstraZeneca plc continue to redefine treatment paradigms through sustained investment in research and development.

Other influential companies such as Bayer AG, Biocon Limited, and BioMarin Pharmaceutical Inc. have established themselves as frontrunners in addressing rare and complex metabolic disorders. Boehringer Ingelheim International GmbH and CHIESI Farmaceutici S.p.A. demonstrate the power of cross-functional strategies and global partnerships in expanding therapeutic reach. Similarly, Dr. Reddy's Laboratories Ltd. and Eli Lilly and Company have made noteworthy strides by integrating cutting-edge technology with clinical precision. Firms like F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, and Glenmark Pharmaceuticals Limited are at the forefront of delivering improved care regimens across diverse patient groups.

The landscape is further enriched by contributions from Johnson & Johnson Services, Inc., Lupin Limited, and Luye Pharma Group Ltd, who continue to push the boundaries of therapeutic innovation. The dominance of Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S is evident in their strategic market positioning and commitment to addressing multiple facets of metabolic disorders. With companies such as Otsuka Holdings Co., Ltd., Pfizer Inc., and Recordati Industria Chimica e Farmaceutica S.p.A. prioritizing research into disease-specific therapies, the market has become a crucible of competitive innovation. Additional significant contributors include Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd., whose efforts further underscore the collective drive toward improved patient outcomes and clinical efficacy.

The synergy between these industry leaders fosters a competitive yet collaborative environment, which promises to sustain momentum and drive meaningful advancements in metabolic disorders therapeutics. This confluence of expertise and innovation ensures that the market remains resilient, dynamic, and capable of responding to evolving healthcare challenges through targeted and transformative strategies.

The report delves into recent significant developments in the Metabolic Disorders Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Acadia Pharmaceuticals Inc., Amgen Inc., Amicus Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biocon Limited, BioMarin Pharmaceutical Inc., Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lupin Limited, Luye Pharma Group Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A, Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd.. Actionable Strategies and Recommendations for Industry Leaders

Given the rapidly evolving nature of the metabolic disorders therapeutics market, industry leaders must adopt a proactive stance to maintain a competitive edge and drive sustainable growth. A key recommendation is to allocate resources toward strategic investments in research and development, particularly in areas that elucidate complex disease mechanisms and pave the way for innovative treatment protocols. Embracing collaborative alliances across academic institutions, biotech startups, and pharmaceutical giants can accelerate the pace of drug discovery and help mitigate the risks associated with clinical trial failures.

Leaders would benefit from harnessing the power of digital transformation to streamline patient engagement and enhance drug delivery systems. Incorporating data analytics and artificial intelligence into research processes can not only optimize clinical trials but also tailor treatments to individual patient profiles. As the market shifts towards personalized medicine, technology-driven strategies become essential to identifying potential treatment efficacies and predicting real-world outcomes.

To expand market reach, it is imperative to diversify distribution strategies by increasing the presence in both traditional and digital channels. Establishing robust networks that connect hospital settings, homecare environments, and specialty centers ensures broader patient access. Moreover, proactive engagement with regulatory bodies to secure favorable guidelines and expedited approval processes for innovative therapies can significantly reduce time-to-market. Industry leaders should closely monitor evolving healthcare policies and align their long-term strategies to accommodate emerging legal and ethical parameters.

Lastly, staying abreast of evolving patient demographics and lifestyle trends is crucial. An in-depth understanding of the diverse needs of adult, geriatric, and pediatric populations can guide product customization and ensure a better fit with the targeted therapeutic segments. By combining strategic foresight with agile operational models, companies are better poised to adapt to market changes and secure a leadership position in this increasingly competitive field.

Conclusion: Charting the Future of Metabolic Disorders Therapeutics

In summary, the metabolic disorders therapeutics market is undergoing a period of extensive transformation driven by rapid technological advancements and evolving patient-centric treatment strategies. The integration of novel therapies, refined segmentation insights, and robust regional dynamics has redefined the landscape in ways that not only improve clinical outcomes but also enhance overall market efficiency. The detailed analysis provided here underscores the importance of innovation, collaboration, and strategic resource allocation in addressing the multifaceted challenges posed by metabolic disorders.

The discussion has highlighted the critical role of segmentation in illuminating key market drivers, including treatment classifications, disease types, therapeutic areas, and patient demographics, which collectively shape the future trajectory of the industry. Furthermore, the examination of regional trends reveals diverse opportunities-ranging from the advanced healthcare ecosystems of the Americas and the balanced approach of Europe, the Middle East, and Africa to the burgeoning potential of the Asia-Pacific region. Industry leaders and innovators are thus encouraged to draw upon these insights to forge strategies that are both adaptive and forward-thinking.

This analysis concludes that the confluence of technological innovation, strategic partnerships, and evolving market dynamics provides a fertile ground for substantial growth. To harness this potential, stakeholders must be agile, informed, and prepared to invest in the long-term sustainability of therapeutic advancements for metabolic disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Shifting lifestyle and dietary patterns contributing to increased incidence of metabolic disorders
      • 5.1.1.2. Rising government initiatives and support for metabolic disorders research
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with product recall and adverse findings in medication
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in CRISPR-Cas9 and other genome-editing tools for treating metabolic disorders
      • 5.1.3.2. Growing potential with increasing collaborations and investments among pharmaceutical companies and healthcare providers
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to patent expirations and the complexity of obtaining and maintaining intellectual property
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Classifications: Increasing benefits of metabolic disorders therapeutics for gene therapies
    • 5.2.2. Disease Type: Proliferating significance of oral medications for treatment of diabetes mellitus
    • 5.2.3. Therapeutic Areas: Growing potential of metabolic disorders therapeutics for the treatment of endocrine disorders
    • 5.2.4. Route Of Administration: Significant advantages of intravenous for drugs that are poorly absorbed orally
    • 5.2.5. Patient Demographics: Increasing application of metabolic disorders therapeutics in adult patients owing to preventing progression through lifestyle modifications
    • 5.2.6. End User: Extending usage of metabolic disorders medications in clinics for small private practices to large multi-specialty facilities
    • 5.2.7. Distribution Channel: Rising popularity of online pharmacies owing to convenience and availability of options
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metabolic Disorders Therapeutics Market, by Treatment Classifications

  • 6.1. Introduction
  • 6.2. Enzyme Replacement Therapies
  • 6.3. Gene Therapies
  • 6.4. Medications & Drugs
  • 6.5. Small Molecule Therapy

7. Metabolic Disorders Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus
    • 7.2.1. Gestational Diabetes
    • 7.2.2. Type 1 Diabetes
    • 7.2.3. Type 2 Diabetes
  • 7.3. Gaucher's Disease
  • 7.4. Hemochromatosis
  • 7.5. Hypercholesterolemia
  • 7.6. Mitochondrial Disorders
  • 7.7. Phenylketonuria (PKU)
  • 7.8. Pompe Disease
  • 7.9. Thyroid Disorders
    • 7.9.1. Hyperthyroidism
    • 7.9.2. Hypothyroidism
  • 7.10. Urea Cycle Disorders
  • 7.11. Wilson's Disease

8. Metabolic Disorders Therapeutics Market, by Therapeutic Areas

  • 8.1. Introduction
  • 8.2. Endocrine Disorders
  • 8.3. Genetic Disorders
  • 8.4. Nutritional Disorders

9. Metabolic Disorders Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Metabolic Disorders Therapeutics Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. Adult Patients
  • 10.3. Geriatric Patients
  • 10.4. Pediatric Patients

11. Metabolic Disorders Therapeutics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals
  • 11.5. Specialty Centers

12. Metabolic Disorders Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Americas Metabolic Disorders Therapeutics Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Metabolic Disorders Therapeutics Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Entero Therapeutics and Journey Therapeutics announce reverse merger to expand precision oncology and metabolic disorders therapies
    • 16.3.2. Chiesi Global Rare Diseases publishes phase 3 BRIGHT study results for pegunigalsidase alfa in fabry disease
    • 16.3.3. Sagimet's Denifanstat granted FDA advance therapy designation for MASH
    • 16.3.4. Amneal and Metsera collaborate to advance therapies for mbesity and Metabolic diseases
    • 16.3.5. Genespire secures USD 52.1m for gene therapy trial targeting rare metabolic disorder
    • 16.3.6. HAYA Therapeutics collaborates with Eli Lilly to target obesity and metabolic disorders using advanced rNA platform
    • 16.3.7. Roche acquires Carmot Therapeutics to advance in metabolic disease treatments
    • 16.3.8. ILBS and INSERM partner for advancements in metabolic disorder therapeutics
    • 16.3.9. Fractyl Health expands metabolic therapeutics pipeline with advanced clinical studies and preclinical results
    • 16.3.10. Marea Therapeutics launches with USD 190 million to develop next-gen cardiometabolic treatments
    • 16.3.11. Metsera strategic launch to innovate obesity and metabolic disease therapies
    • 16.3.12. Orchard Therapeutics U.S. launch of Lenmeldy for treating early-onset metachromatic leukodystrophy
    • 16.3.13. BioAge secures USD 170 million in Series D to advance obesity and metabolic therapies
    • 16.3.14. MIT secures USD 65.67 million for innovative metabolic disorder treatments
    • 16.3.15. Novo Nordisk collaborates with Omega Therapeutics and Cellarity on metabolic disorder innovations
    • 16.3.16. Chiesi Farmaceutici to acquire Amryt Pharma, enhancing rare disease therapeutics portfolio
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. F. Hoffmann-La Roche Ltd
    • 16.4.2. Lupin Limited
    • 16.4.3. Eli Lilly and Company
    • 16.4.4. Pfizer Inc.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Acadia Pharmaceuticals Inc.
  • 4. Amgen Inc.
  • 5. Amicus Therapeutics, Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca plc
  • 8. Bayer AG
  • 9. Biocon Limited
  • 10. BioMarin Pharmaceutical Inc.
  • 11. Boehringer Ingelheim International GmbH
  • 12. CHIESI Farmaceutici S.p.A.
  • 13. Dr. Reddy's Laboratories Ltd.
  • 14. Eli Lilly and Company
  • 15. F. Hoffmann-La Roche Ltd
  • 16. GlaxoSmithKline PLC
  • 17. Glenmark Pharmaceuticals Limited
  • 18. Johnson & Johnson Services, Inc.
  • 19. Lupin Limited
  • 20. Luye Pharma Group Ltd
  • 21. Merck & Co., Inc.
  • 22. Novartis AG
  • 23. Novo Nordisk A/S
  • 24. Otsuka Holdings Co., Ltd.
  • 25. Pfizer Inc.
  • 26. Recordati Industria Chimica e Farmaceutica S.p.A
  • 27. Sanofi S.A.
  • 28. Sumitomo Pharma Co., Ltd.
  • 29. Sun Pharmaceutical Industries
  • 30. Takeda Pharmaceutical Company Limited
  • 31. Teva Pharmaceutical Industries Ltd.
  • 32. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MEDICATIONS & DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GAUCHER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEMOCHROMATOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PHENYLKETONURIA (PKU), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY WILSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 203. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 212. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 214. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 221. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 223. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 240. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 242. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 249. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 251. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 258. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 260. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 267. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 269. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 276. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 278. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 285. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 287. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE